1、 PIHA J,KAAJA R.Effects of moxonidine and metoprolol in penile circulation in hypertensive men with erectile dysfunction:Results of a pilot study[J].Int J Impot Res,2003,15(4):287-289. PIHA J,KAAJA R.Effects of moxonidine and metoprolol in penile circulation in hypertensive men with erectile dysfunction:Results of a pilot study[J].Int J Impot Res,2003,15(4):287-289.
2、 ZAHALKA A H,FRAM E,LIN W,et al.Use of beta-blocker types and risk of incident prostate cancer in a multiethnic population[J].Urol Oncol,2020,38(10):794.e11-794.e16. ZAHALKA A H,FRAM E,LIN W,et al.Use of beta-blocker types and risk of incident prostate cancer in a multiethnic population[J].Urol Oncol,2020,38(10):794.e11-794.e16.
3、 ZHENG G,SUNDQUIST J,SUNDQUIST K,et al.Beta-blockers use and risk of breast cancer in women with hypertension[J].Cancer Epidemiol Biomarkers Prev,2021,30(5):965-973. ZHENG G,SUNDQUIST J,SUNDQUIST K,et al.Beta-blockers use and risk of breast cancer in women with hypertension[J].Cancer Epidemiol Biomarkers Prev,2021,30(5):965-973.
4、 GELSON E,CURRY R,GATZOULIS M A,et al.Effect of maternal heart disease on fetal growth[J].Obstet Gynecol,2011,117(4):886-891. GELSON E,CURRY R,GATZOULIS M A,et al.Effect of maternal heart disease on fetal growth[J].Obstet Gynecol,2011,117(4):886-891.
5、 DUAN L,NG A,CHEN W,et al.Beta-blocker subtypes and risk of low birth weight in newborns[J].J Clin Hypertens(Greenwich),2018,20(11):1603-1609. DUAN L,NG A,CHEN W,et al.Beta-blocker subtypes and risk of low birth weight in newborns[J].J Clin Hypertens(Greenwich),2018,20(11):1603-1609.
6、 刘凤玲. 心血管病住院患者并发肺部感染的危险因素分析[J].临床合理用药杂志,2016,9(22):133-134. 刘凤玲. 心血管病住院患者并发肺部感染的危险因素分析[J].临床合理用药杂志,2016,9(22):133-134.
7、 张新花.心血管病住院患者并发肺部感染的危险因素及防治措施[J].临床医药文献电子杂志,2017,4(23):4370,4372. 张新花.心血管病住院患者并发肺部感染的危险因素及防治措施[J].临床医药文献电子杂志,2017,4(23):4370,4372.
8、 SEBASTIAN S,STEIN L K,DHAMOON M S.Infection as a cardiovascular trigger:Associations between different organ system infections and cardiovascular events[J].Am J Med,2020,133(12):1437-1443. SEBASTIAN S,STEIN L K,DHAMOON M S.Infection as a cardiovascular trigger:Associations between different organ system infections and cardiovascular events[J].Am J Med,2020,133(12):1437-1443.
9、 董娜.心血管病住院患者并发肺部感染的危险因素分析[J].中西医结合心血管病电子杂志,2017,5(14):47,50. 董娜.心血管病住院患者并发肺部感染的危险因素分析[J].中西医结合心血管病电子杂志,2017,5(14):47,50.
10、 张欣颖,刘亚梅,龚爽.心血管疾病住院患者并发医院感染的危险因素及护理措施[J].长春中医药大学学报,2018,34(3):562-564. 张欣颖,刘亚梅,龚爽.心血管疾病住院患者并发医院感染的危险因素及护理措施[J].长春中医药大学学报,2018,34(3):562-564.
11、 李爱珍,王风燕,王红丽,等.心血管内科住院患者医院感染的病原菌分布及危险因素分析[J].中国实验诊断学,2021,25(10):1500-1501. 李爱珍,王风燕,王红丽,等.心血管内科住院患者医院感染的病原菌分布及危险因素分析[J].中国实验诊断学,2021,25(10):1500-1501.
12、 厉晓玲. 心血管疾病住院患者并发医院感染的危险因素与护理干预措施[J].心血管病防治知识,2022,12(20):79-81. 厉晓玲. 心血管疾病住院患者并发医院感染的危险因素与护理干预措施[J].心血管病防治知识,2022,12(20):79-81.
13、 GOLDNER J A.Metoprolol-induced visual hallucinations:a case series[J].J Med Case Rep,2012(6):65. GOLDNER J A.Metoprolol-induced visual hallucinations:a case series[J].J Med Case Rep,2012(6):65.
14、 HEUSCH G,KLEINBONGARD P.Is metoprolol more cardioprotective than other beta-blockers?[J].Eur Heart J,2020,41(46):4441-4443. HEUSCH G,KLEINBONGARD P.Is metoprolol more cardioprotective than other beta-blockers?[J].Eur Heart J,2020,41(46):4441-4443.
15、 ZAMIR A,HUSSAIN I,REHMAN A U,et al.Clinical pharmacokinetics of metoprolol:A systematic review[J].Clin Pharmacokinet,2022,61(8):1095-1114. ZAMIR A,HUSSAIN I,REHMAN A U,et al.Clinical pharmacokinetics of metoprolol:A systematic review[J].Clin Pharmacokinet,2022,61(8):1095-1114.
16、 GEDDE-DAHL A,SPIGSET O,MOLDEN E.Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway[J].Eur J Clin Pharmacol,2022,78(10):1623-1632. GEDDE-DAHL A,SPIGSET O,MOLDEN E.Co-prescription of metoprolol and CYP2D6-inhibiting antidepressants before and after implementation of an optimized drug interaction database in Norway[J].Eur J Clin Pharmacol,2022,78(10):1623-1632.
17、 MAIDEEN N M P,RAJKAPOOR B,MUTHUSAMY S,et al.A review on pharmacokinetic and pharmacodynamic drug interactions of adrenergic β-blockers with clinically relevant drugs-an overview[J].Curr Drug Metab,2021,22(9):672-682. MAIDEEN N M P,RAJKAPOOR B,MUTHUSAMY S,et al.A review on pharmacokinetic and pharmacodynamic drug interactions of adrenergic β-blockers with clinically relevant drugs-an overview[J].Curr Drug Metab,2021,22(9):672-682.
18、 SAKAEDA T,TAMON A,KADOYAMA K,et al.Data mining of the public version of the FDA Adverse Event Reporting System[J].Int J Med Sci,2013,10(7):796-803. SAKAEDA T,TAMON A,KADOYAMA K,et al.Data mining of the public version of the FDA Adverse Event Reporting System[J].Int J Med Sci,2013,10(7):796-803.
19、 方芳,隋小芳,方舟,等.ADRB1、CYP2D6*10基因多态性对美托洛尔药动学、药效学的影响[C].中国天津:2015. 方芳,隋小芳,方舟,等.ADRB1、CYP2D6*10基因多态性对美托洛尔药动学、药效学的影响[C].中国天津:2015.
20、 沈鹃琴,王林,徐少坤,等.ADRB_1基因多态性对高血压患者美托洛尔缓释片疗效的影响[J].心电与循环,2023,42(2):145-148. 沈鹃琴,王林,徐少坤,等.ADRB_1基因多态性对高血压患者美托洛尔缓释片疗效的影响[J].心电与循环,2023,42(2):145-148.
21、 孙亚红,林阳,石秀锦.2467例中国汉族患者CYP2D6基因多态性分布频率研究[J].临床药物治疗杂志,2023,21(6):36-40. 孙亚红,林阳,石秀锦.2467例中国汉族患者CYP2D6基因多态性分布频率研究[J].临床药物治疗杂志,2023,21(6):36-40.
22、 MELOCHE M,KHAZAKA M,KASSEM I,et al.CYP2D6 polymorphism and its impact on the clinical response to metoprolol:A systematic review and meta-analysis[J].Br J Clin Pharmacol,2020,86(6):1015-1033. MELOCHE M,KHAZAKA M,KASSEM I,et al.CYP2D6 polymorphism and its impact on the clinical response to metoprolol:A systematic review and meta-analysis[J].Br J Clin Pharmacol,2020,86(6):1015-1033.
23、 侯宇鹏. 伊伐布雷定对冠心病合并心律失常患者心率变异性的影响及对心房颤动的防治效果[J].广州医药,2023,54(12):83-88. 侯宇鹏. 伊伐布雷定对冠心病合并心律失常患者心率变异性的影响及对心房颤动的防治效果[J].广州医药,2023,54(12):83-88.
24、 CHEN J,ZHENG J,ZHU Z,et al.Impact of the CYP2D6 genotype on metoprolol tolerance and adverse events in elderly Chinese patients with cardiovascular diseases[J].Front Pharmacol,2022,13:876392. CHEN J,ZHENG J,ZHU Z,et al.Impact of the CYP2D6 genotype on metoprolol tolerance and adverse events in elderly Chinese patients with cardiovascular diseases[J].Front Pharmacol,2022,13:876392.
25、 鲍骏,王晓彦,邹丽婷,等.琥珀酸美托洛尔联合诺欣妥对老年充血性心力衰竭患者心功能指标和凝血功能的影响[J].中国老年学杂志,2023,43(15):3602-3605. 鲍骏,王晓彦,邹丽婷,等.琥珀酸美托洛尔联合诺欣妥对老年充血性心力衰竭患者心功能指标和凝血功能的影响[J].中国老年学杂志,2023,43(15):3602-3605.
26、 邱秀君,陈越,冯文才.药物服务干预对老年高血压患者的治疗及用药安全性的影响[J].广州医药,2023,54(12):49-54. 邱秀君,陈越,冯文才.药物服务干预对老年高血压患者的治疗及用药安全性的影响[J].广州医药,2023,54(12):49-54.
27、 LADDU D,MA J,KAAR J,et al.Health behavior change programs in primary care and community practices for cardiovascular disease prevention and risk factor management among midlife and older adults:A scientific statement from the American heart association[J].Circulation,2021,144(24):e533-e549. LADDU D,MA J,KAAR J,et al.Health behavior change programs in primary care and community practices for cardiovascular disease prevention and risk factor management among midlife and older adults:A scientific statement from the American heart association[J].Circulation,2021,144(24):e533-e549.
